Stocks
Shattuck Labs, Inc.STTK
NASDAQHealthcareBiotechnology$5.58
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for autoimmune and oncological diseases, with a focus on its lead product candidate, ALPN-303, a dual antagonist targeting the BAFF and APRIL pathways. Investors track the stock for its pipeline progress and upcoming clinical data readouts.
52W Range: $1.72-$8.33
Congressional Interest in Shattuck Labs, Inc. (STTK)
No congressional trades have been disclosed for Shattuck Labs, Inc. (STTK) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading STTK?
No congressional trades found for this stock.